DK2814963T3 - Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein - Google Patents

Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein Download PDF

Info

Publication number
DK2814963T3
DK2814963T3 DK13704552.2T DK13704552T DK2814963T3 DK 2814963 T3 DK2814963 T3 DK 2814963T3 DK 13704552 T DK13704552 T DK 13704552T DK 2814963 T3 DK2814963 T3 DK 2814963T3
Authority
DK
Denmark
Prior art keywords
histonic
coding
poly
sequence
nucleic acid
Prior art date
Application number
DK13704552.2T
Other languages
Danish (da)
English (en)
Inventor
Andreas Thess
Thomas Schlake
Jochen Probst
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Application granted granted Critical
Publication of DK2814963T3 publication Critical patent/DK2814963T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
DK13704552.2T 2012-02-15 2013-02-15 Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein DK2814963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/000671 WO2013120497A1 (en) 2012-02-15 2012-02-15 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
PCT/EP2013/000461 WO2013120629A1 (en) 2012-02-15 2013-02-15 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

Publications (1)

Publication Number Publication Date
DK2814963T3 true DK2814963T3 (da) 2020-07-27

Family

ID=47720472

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13704552.2T DK2814963T3 (da) 2012-02-15 2013-02-15 Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein

Country Status (15)

Country Link
US (5) US9447431B2 (enrdf_load_html_response)
EP (2) EP3741859A1 (enrdf_load_html_response)
JP (3) JP6357111B2 (enrdf_load_html_response)
KR (1) KR102072013B1 (enrdf_load_html_response)
CN (2) CN104114705B (enrdf_load_html_response)
AU (1) AU2013220749B2 (enrdf_load_html_response)
BR (1) BR112014019627A2 (enrdf_load_html_response)
CA (1) CA2862476C (enrdf_load_html_response)
DK (1) DK2814963T3 (enrdf_load_html_response)
ES (1) ES2806678T3 (enrdf_load_html_response)
IN (1) IN2014DN05670A (enrdf_load_html_response)
MX (1) MX359953B (enrdf_load_html_response)
RU (1) RU2634391C2 (enrdf_load_html_response)
SG (2) SG10201606784QA (enrdf_load_html_response)
WO (2) WO2013120497A1 (enrdf_load_html_response)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
SG11201405545XA (en) 2012-03-27 2014-11-27 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
US9683233B2 (en) 2012-03-27 2017-06-20 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
KR102186497B1 (ko) 2012-03-27 2020-12-04 큐어백 아게 인공 핵산 분자
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
PL2970456T3 (pl) 2013-03-14 2022-01-31 Translate Bio, Inc. Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna
KR102248744B1 (ko) 2013-03-14 2021-05-06 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
HUE071526T2 (hu) 2013-03-15 2025-09-28 Translate Bio Inc Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
JP6896421B2 (ja) 2013-08-21 2021-06-30 キュアバック アーゲー 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
ES2702466T3 (es) 2013-08-21 2019-03-01 Curevac Ag Procedimiento para aumentar la expresión de proteínas codificadas por ARN
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
EP3090052B1 (en) * 2013-12-30 2018-06-13 CureVac AG Artificial nucleic acid molecules
WO2015101415A1 (en) * 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US20170183389A1 (en) * 2014-04-24 2017-06-29 Accurna, Inc. Method for improving protein expression, and composition for protein expression
WO2015188933A1 (en) 2014-06-10 2015-12-17 Curevac Ag Methods and means for enhancing rna production
CN111454165B (zh) 2014-06-25 2024-01-05 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
EP3227320B1 (en) * 2014-12-03 2019-07-03 Florida State University Research Foundation, Inc. Modified fibroblast growth factor 1 (fgf-1) polypeptides with increased binding affinity for heparin and associated methods
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
SG11201704681QA (en) * 2014-12-30 2017-07-28 Curevac Ag Artificial nucleic acid molecules
US10618944B2 (en) 2015-02-27 2020-04-14 Saint Louis University Tumor suppressor SALL1 as a therapeutic agent for treating cancer
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
CN107635587A (zh) 2015-05-20 2018-01-26 库瑞瓦格股份公司 包含长链rna的干燥粉末组合物
WO2016184576A2 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
CN113897350A (zh) 2015-05-29 2022-01-07 库瑞瓦格房地产有限公司 包括至少一个切向流过滤步骤的产生和纯化rna的方法
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
EP4420679A3 (en) 2015-06-29 2024-12-04 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
PL4155409T3 (pl) * 2015-08-10 2024-06-17 CureVac Manufacturing GmbH Sposób zwiększania replikacji kolistej cząsteczki dna
SG10201913629VA (en) 2015-08-28 2020-03-30 Curevac Ag Artificial nucleic acid molecules
HUE057613T2 (hu) 2015-09-17 2022-05-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
DK3350333T3 (da) 2015-09-17 2022-01-31 Modernatx Inc Polynukleotider, der indeholder en stabiliserende haleregion
WO2017062513A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EP3362461B1 (en) 2015-10-16 2022-03-16 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
AU2016340183A1 (en) 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017070626A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Respiratory virus vaccines
CA3003055C (en) 2015-10-28 2023-08-01 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
PL3394030T3 (pl) 2015-12-22 2022-04-11 Modernatx, Inc. Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
EP3319622B1 (en) 2015-12-22 2020-02-12 CureVac AG Method for producing rna molecule compositions
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452493B1 (en) 2016-05-04 2025-01-15 CureVac SE Nucleic acid molecules and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP3458590B9 (en) 2016-05-18 2021-08-18 ModernaTX, Inc. Polynucleotides encoding -galactosidase a for the treatment of fabry disease
JP7145579B2 (ja) 2016-06-09 2022-10-03 キュアバック アーゲー 核酸カーゴ用のハイブリッド担体
JP2019522047A (ja) 2016-06-13 2019-08-08 トランスレイト バイオ， インコーポレイテッド オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーｒｎａ療法
CN105920585B (zh) * 2016-06-13 2019-07-09 浙江生创精准医疗科技有限公司 Mcp-1单独或与其他细胞因子联合在治疗肝纤维化中的用途
JP2019525901A (ja) 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
JP2019518775A (ja) * 2016-06-22 2019-07-04 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ カナバン病の治療
EP3512537B1 (en) * 2016-09-15 2023-11-01 Elicera Therapeutics AB T-cell immunotherapy
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3538550A1 (en) 2016-11-10 2019-09-18 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Or10h1 modulators and uses thereof
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
US11464836B2 (en) 2016-12-08 2022-10-11 Curevac Ag RNA for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
SG11201906392WA (en) 2017-01-11 2019-08-27 Univ Pennsylvania Nucleoside-modified rna for inducing an immune response against zika virus
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
JP6949131B2 (ja) 2017-02-28 2021-10-13 サノフイＳａｎｏｆｉ 治療用ｒｎａ
ES3020935T3 (en) 2017-03-15 2025-05-23 Modernatx Inc Lipid nanoparticle formulation
JP7167049B2 (ja) 2017-03-15 2022-11-08 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物及び組成物
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MX2019011215A (es) 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
CN107245510B (zh) * 2017-05-23 2020-10-30 中山大学附属第三医院 用于示踪免疫细胞的试剂盒及方法
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
CN111328287A (zh) 2017-07-04 2020-06-23 库瑞瓦格股份公司 新型核酸分子
KR102659791B1 (ko) * 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
EP3437650A1 (en) * 2017-07-31 2019-02-06 Accanis Biotech F&E GmbH & Co KG Treatment of local skin hypotrophy conditions
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3668834B1 (en) 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR PREPARING MODIFIED RNA
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
CN107590533B (zh) * 2017-08-29 2020-07-31 中国科学院计算技术研究所 一种用于深度神经网络的压缩装置
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US11692002B2 (en) 2017-11-08 2023-07-04 CureVac SE RNA sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
WO2019126593A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
KR20210003811A (ko) 2018-04-17 2021-01-14 큐어백 아게 백신 접종을 위한 신규 rsv rna 분자 및 조성물
CN112334579A (zh) 2018-06-28 2021-02-05 库瑞瓦格股份公司 用于rna体外转录的生物反应器
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
AU2020214425A1 (en) 2019-01-31 2021-08-19 Modernatx, Inc. Vortex mixers and associated methods, systems, and apparatuses thereof
CA3128215A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN120022289A (zh) * 2019-05-24 2025-05-23 艾姆皮瑞克公司 血管生成素样7（angptl7）相关疾病的治疗
CA3146023A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
CN112646009B (zh) * 2019-08-27 2022-02-08 上海交通大学 灵芝免疫调节蛋白突变体及应用
CN110548132B (zh) * 2019-10-24 2023-04-25 安徽医科大学附属巢湖医院 TGF-β1蛋白在制备治疗抑郁症的药物中的应用
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
IL295232A (en) * 2020-02-10 2022-10-01 Univ Utah Res Found High molecular weight heparin compositions and methods for diagnosing, treating and monitoring eosinophil mediated inflammatory diseases
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
ES2992639T3 (en) 2020-04-09 2024-12-16 Suzhou Abogen Biosciences Co Ltd Lipid nanoparticle composition
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
CA3182994A1 (en) 2020-06-30 2022-01-06 Bo YING Lipid compounds and lipid nanoparticle compositions
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
BR112023000327A2 (pt) 2020-07-16 2023-01-31 Acuitas Therapeutics Inc Lipídeos catiônicos para o uso em nanopartículas lipídicas
MX2023001120A (es) 2020-07-31 2023-02-22 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
TW202214566A (zh) 2020-08-20 2022-04-16 大陸商蘇州艾博生物科技有限公司 脂質化合物及脂質奈米粒子組合物
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN112175988B (zh) * 2020-09-15 2021-06-15 广东省农业科学院蔬菜研究所 黄瓜韧皮部凝集素CsPL1在抗瓜类疫病中的应用
JP2023547507A (ja) 2020-11-03 2023-11-10 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
CN112516288B (zh) * 2020-12-22 2023-04-18 西藏阿那达生物医药科技有限责任公司 N-糖基化修饰之灵芝免疫调节蛋白的应用
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
EP4301402A1 (en) 2021-03-03 2024-01-10 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Bispecific antibodies enhancing cell mediated immune responses
WO2022241130A1 (en) 2021-05-12 2022-11-17 NexEos Diagnostics, Inc. Methods of manufacturing a high molecular weight heparin compound
KR20240013087A (ko) 2021-05-24 2024-01-30 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
TW202527987A (zh) 2021-06-25 2025-07-16 日商中外製藥股份有限公司 抗ctla-4抗體的用途
JP7472405B2 (ja) 2021-06-25 2024-04-22 中外製薬株式会社 抗ｃｔｌａ－４抗体
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
JP2024533865A (ja) 2021-09-14 2024-09-12 レナゲード セラピューティクス マネージメント インコーポレイテッド 環状脂質及びその使用方法
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
WO2023056917A1 (en) 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
CN113813369B (zh) * 2021-11-09 2023-09-22 浙江省农业科学院 用于预防/治疗仔猪肠道损伤的egf/mmt复合物
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用
EP4448485A2 (en) 2021-12-16 2024-10-23 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
AU2022422983A1 (en) 2021-12-23 2024-05-16 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
CN114711192B (zh) * 2022-04-13 2022-11-29 中国科学院西北高原生物研究所 一种长效抑郁症动物模型的构建试剂盒及构建方法
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4572745A1 (en) 2022-08-18 2025-06-25 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024133940A2 (en) 2022-12-23 2024-06-27 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
CN117430713B (zh) * 2023-09-12 2025-07-29 四川三优康生物技术有限公司 一种猪EGF，Ghrelin和IGF-1共表达的融合蛋白、核酸分子、生物材料及应用和产品
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025119999A1 (en) 2023-12-04 2025-06-12 Universität Duisburg-Essen Extracellular vesicle based vaccine platform
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
CN119060155B (zh) * 2024-11-07 2025-03-07 山东大学 一种蛋白在调节肠道稳态及抵抗致病菌感染中的应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
JP2001518804A (ja) * 1997-03-21 2001-10-16 エンゾー セラピューティクス インコーポレイテッド ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CA2457959C (en) 2001-06-05 2014-10-28 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
WO2003038049A2 (en) 2001-10-29 2003-05-08 Renovis, Inc. Method for isolating cell-type specific mrnas
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CA2514184C (en) 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
NZ546554A (en) 2003-10-10 2009-04-30 Powderject Vaccines Inc Nucleic acid constructs
PL2292754T3 (pl) * 2003-10-24 2013-06-28 Selexis Sa Wysokowydajny transfer genu i ekspresja w komórkach ssaczych przez procedurę wielokrotnej transfekcji sekwencji regionu przylegania do macierzy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
LT2578685T (lt) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
RU2545701C2 (ru) 2008-01-31 2015-04-10 Куревак Гмбх НУКЛЕИНОВЫЕ КИСЛОТЫ ФОРМУЛЫ (I) (NuGlXmGnNv)a И ИХ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИММУННОСТИМУЛИРУЮЩИХ АГЕНТОВ/АДЪЮВАНТОВ
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
WO2010132867A1 (en) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
SG186706A1 (en) 2010-07-30 2013-02-28 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
SG11201405545XA (en) 2012-03-27 2014-11-27 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
KR102186497B1 (ko) 2012-03-27 2020-12-04 큐어백 아게 인공 핵산 분자
US9683233B2 (en) 2012-03-27 2017-06-20 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
AU2014310930A1 (en) 2013-08-21 2016-01-21 Curevac Ag Composition and vaccine for treating prostate cancer
SG11201510748PA (en) 2013-08-21 2016-03-30 Curevac Ag Composition and vaccine for treating lung cancer
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
ES2702466T3 (es) 2013-08-21 2019-03-01 Curevac Ag Procedimiento para aumentar la expresión de proteínas codificadas por ARN
JP6896421B2 (ja) 2013-08-21 2021-06-30 キュアバック アーゲー 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
AU2014375402B2 (en) * 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015188933A1 (en) 2014-06-10 2015-12-17 Curevac Ag Methods and means for enhancing rna production
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
SG11201704681QA (en) 2014-12-30 2017-07-28 Curevac Ag Artificial nucleic acid molecules
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
SG11201708681SA (en) 2015-04-30 2017-11-29 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
WO2016184576A2 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
CN107635587A (zh) 2015-05-20 2018-01-26 库瑞瓦格股份公司 包含长链rna的干燥粉末组合物
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
CN113897350A (zh) 2015-05-29 2022-01-07 库瑞瓦格房地产有限公司 包括至少一个切向流过滤步骤的产生和纯化rna的方法
WO2016203025A1 (en) 2015-06-17 2016-12-22 Curevac Ag Vaccine composition
EP3317424B1 (en) 2015-07-01 2023-09-06 CureVac Manufacturing GmbH Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
EP3332019B1 (en) 2015-08-07 2019-12-18 CureVac AG Process for the in vivo production of rna in a host cell
PL4155409T3 (pl) 2015-08-10 2024-06-17 CureVac Manufacturing GmbH Sposób zwiększania replikacji kolistej cząsteczki dna
SG10201913629VA (en) 2015-08-28 2020-03-30 Curevac Ag Artificial nucleic acid molecules

Also Published As

Publication number Publication date
ES2806678T3 (es) 2021-02-18
CN104114705A (zh) 2014-10-22
US20180185517A1 (en) 2018-07-05
WO2013120629A1 (en) 2013-08-22
RU2634391C2 (ru) 2017-10-26
SG10201606784QA (en) 2016-12-29
KR102072013B1 (ko) 2020-01-31
CN108570468B (zh) 2022-11-25
SG11201403944RA (en) 2014-10-30
US20170056529A1 (en) 2017-03-02
US20210060181A1 (en) 2021-03-04
JP2018110588A (ja) 2018-07-19
US10111968B2 (en) 2018-10-30
CA2862476C (en) 2021-06-08
JP2015508646A (ja) 2015-03-23
CN104114705B (zh) 2018-06-01
US10898589B2 (en) 2021-01-26
CN108570468A (zh) 2018-09-25
WO2013120497A1 (en) 2013-08-22
US20150057340A1 (en) 2015-02-26
EP2814963B1 (en) 2020-04-29
IN2014DN05670A (enrdf_load_html_response) 2015-04-03
CA2862476A1 (en) 2013-08-22
JP6922038B2 (ja) 2021-08-18
US10610605B2 (en) 2020-04-07
US9447431B2 (en) 2016-09-20
US20180177894A1 (en) 2018-06-28
JP6720235B2 (ja) 2020-07-08
EP2814963A1 (en) 2014-12-24
MX359953B (es) 2018-10-17
RU2014137109A (ru) 2016-04-10
KR20140125434A (ko) 2014-10-28
AU2013220749B2 (en) 2018-05-17
MX2014009884A (es) 2014-11-10
EP3741859A1 (en) 2020-11-25
AU2013220749A1 (en) 2014-07-24
JP6357111B2 (ja) 2018-07-11
BR112014019627A2 (pt) 2017-06-27
JP2020191871A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
DK2814963T3 (da) Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein
CY2020020I1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
IL272532A (en) Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
DK2945647T3 (da) Immunogene wt-1-peptider og anvendelsesmetoder deraf
DK2892330T3 (da) Genetisk modificeret mus og fremgangsmåder til anvendelse deraf
EP2802347A4 (en) IMMUNOGENIC WT-1 PEPTIDES AND METHOD OF USE THEREOF
EP2895083A4 (en) LIGATOR AND METHOD FOR ITS USE
HUE062740T2 (hu) GLP-1 peptidek készítményei és elõállításuk
DK2603590T3 (da) Nukleinsyre omfattende eller kodende for et histon stem-loop og en poly(a) se-kvens eller et polyadenyleringssignal til forøgelse af ekspressionen af et kodet protein
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK3489254T3 (da) Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
DK3744835T3 (da) Dna modificerende fusionsproteiner og metoder til anvendelse deraf
EP2563435A4 (en) ADMINISTRATION OF ULTRA PURE NITROGEN MONOXIDE (NO)
PL2847996T3 (pl) Sposoby wykonywania predykcji wektora ruchu, sposoby kodowania i dekodowania oraz służące do tego urządzenia
EP2809144A4 (en) NEW CLASSES OF GLYPHOSATE RESISTANCE GENES
BR112014031828A2 (pt) preparação, usos e formas sólidas de ácido obeticólico
EP2915557A4 (en) Retinoic acid-MICRO NEEDLE
EP3689365C0 (en) USE OF LONG-ACTING GLP-1 PEPTIDES
EP2999474A4 (en) THERAPEUTIC AND METHOD FOR USE
DK3666827T3 (da) Tørre silikonegeler og deres fremstillingsmetoder
PL2934093T3 (pl) Trwała transformacja populacji i sposób ochrony biologicznej z wykorzystaniem zasad haploinsuficjencji i poddominacji
HUE045668T2 (hu) Oldat készítmények módosított anti-IL-23p19 antitestekbõl
BR302012006546S1 (pt) Configuracao aplicada em instrumento medico
BR112013017488A2 (pt) peptídeos imunogênicos multiméricos e monoméricos